Abstract: OBJECTIVE To systematically evaluate the protective effect of sacubitril/valsartan vs angiotensin-converting enzyme inhibitors/angiotensin retor blockers(ACEI/ARB) on renal function. METHODS Databases such as Wanfang, CNKI, PubMed, Embase, ClinicalTrials.gov and The Cochrane Library were searched to collect randomized controlled trials of patients treated with sacubitril/valsartan and ACEI/ARB. The retrieval period was from the self-established database to June 12, 2021. Literature screening and data extraction were conducted independently by two researchers. The included studies were evaluated according to the risk bias assessment tool in the Cochrane Collaborative System Rater's Manual, and meta-analysis was performed using RevMan 5.3 software. Summarize data into binary variables and 95% confidence interval the heterogeneity was assessed with the I² test. RESULTS The 11 studies met the study criteria, including 18 966 patients. Compared with ACEI/ARB, sacubitril/valsartan reduced the risk of worsening renal functionRR=0.89, 95%CI(0.80, 0.99), P=0.03; sacubitril/valsartan reduced the risk of renal function deterioration in patients with HFRR=0.87, 95%CI(0.78, 0.97), P=0.02, but it can't reduce the risk of renal function deterioration in patients with non-HFRR=1.04, 95%CI(0.80, 1.37), P=0.76; sacubitril/valsartan reduced the risk of renal function deterioration in heart failure patients with preserved ejection fractionRR=0.85, 95%CI(0.74, 0.97), P=0.02, and reduced the risk of renal function deterioration in heart failure patients with reduced ejection fractionRR=0.91, 95%CI(0.75, 1.10), P=0.34; in patients with HF, sacubitril/valsartan reduced the risk of of renal function deterioration compared with ACEIRR=0.95, 95%CI(0.83, 1.10), P=0.51, and it reduced the risk of renal function deterioration compared with ARBRR=0.74, 95%CI(0.61, 0.89), P=0.002. CONCLUSION This research provides evidence that sacubitril/valsartan has better protection of renal function in patients with heart failure than ACEI/ARB, but the differences were different among different heart failure types and control drug subgroups, while it is similar to ACEI/ARB in non-heart failure patients.